102 related articles for article (PubMed ID: 8757522)
1. GM-CSF raises serum levels of beta 2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia.
Itälä M; Pelliniemi TT; Remes K
Br J Haematol; 1996 Jul; 94(1):129-32. PubMed ID: 8757522
[TBL] [Abstract][Full Text] [Related]
2. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
[TBL] [Abstract][Full Text] [Related]
4. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
[TBL] [Abstract][Full Text] [Related]
5. GM-CSF treatment in patients with B-chronic lymphocytic leukemia.
de Nully Brown P; Hansen MM
Leuk Lymphoma; 1999 Jan; 32(3-4):365-8. PubMed ID: 10037035
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia.
Stelmach P; Błoński JZ; Wawrzyniak E; Schweiger PE; Wilandt A; Majak PE; Robak T
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1321-1330. PubMed ID: 28100842
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections.
Itälä M; Pelliniemi TT; Remes K; Vanhatalo S; Vainio O
Leuk Lymphoma; 1998 Dec; 32(1-2):165-74. PubMed ID: 10037012
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum during induction treatment of acute leukaemia.
Sallerfors B; Olofsson T
Br J Haematol; 1991 Jul; 78(3):343-51. PubMed ID: 1714757
[TBL] [Abstract][Full Text] [Related]
9. [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors].
Xu W; Shen QD; Yu H; Qiao C; Wu YJ; Liu Q; Zhu DX; Miao KR; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):8-12. PubMed ID: 19563027
[TBL] [Abstract][Full Text] [Related]
10. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
Lehtinen T
Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia and prognostic factors.
Mozaheb Z; Hasanzadeh NazarAbadi MH; Aghaee MA
Asian Pac J Cancer Prev; 2012; 13(7):3009-13. PubMed ID: 22994703
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic significance of lactate dehydrogenase and beta2-microglobulin in chronic lymphocytic leukemia].
Shen QD; Xu W; Yu H; Li L; Zhang SJ; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1305-8. PubMed ID: 18088490
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.
Magnac C; Porcher R; Davi F; Nataf J; Payelle-Brogard B; Tang RP; Oppezzo P; Lévy V; Dighiero G; Ajchenbaum-Cymbalista F
Leukemia; 2003 Jan; 17(1):133-7. PubMed ID: 12529670
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
15. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia.
Di Giovanni S; Valentini G; Carducci P; Giallonardo P
Acta Haematol; 1989; 81(4):181-5. PubMed ID: 2502891
[TBL] [Abstract][Full Text] [Related]
16. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological significance of serum tumor markers in adult T-cell leukemia.
Sadamori N
Leuk Lymphoma; 1996 Aug; 22(5-6):415-9. PubMed ID: 8882954
[TBL] [Abstract][Full Text] [Related]
18. [Autoantibody against granulocyte-macrophage colony-stimulating factor and other serum markers in pulmonary alveolar proteinosis].
Xu KF; Chen Y; Guo ZJ; Zhu YJ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Dec; 27(12):824-8. PubMed ID: 15730782
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.
Hallek M; Langenmayer I; Nerl C; Knauf W; Dietzfelbinger H; Adorf D; Ostwald M; Busch R; Kuhn-Hallek I; Thiel E; Emmerich B
Blood; 1999 Mar; 93(5):1732-7. PubMed ID: 10029603
[TBL] [Abstract][Full Text] [Related]
20. Interleukins, TNF-alpha and beta-2M in patients with B cell chronic lymphocytic leukemia.
Mavridis AK; Tsiara S; Makis A; Chaidos A; Christou L; Seferiadis K; Bourantas KL
J Exp Clin Cancer Res; 1998 Dec; 17(4):445-8. PubMed ID: 10089066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
